

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
27 April 2024 :: Issue 748
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



Global Immunization

Global immunization efforts have saved at least 154 million lives over the past 50 years

24 April 2024 *Joint News Release*

A major landmark study to be published by The Lancet reveals that global immunization efforts have saved an estimated 154 million lives – or the equivalent of 6 lives every minute of every year – over the past 50 years. **The vast majority of lives saved – 101 million – were those of infants.**

The study, led by the World Health Organization (WHO), shows that immunization is the **single greatest contribution of any health intervention to ensuring babies not only see their first birthdays** but continue leading healthy lives into adulthood.

Of the vaccines included in the study, the **measles vaccination had the most significant impact on reducing infant mortality, accounting for 60% of the lives saved** due to immunization. This vaccine will likely remain the top contributor to preventing deaths in the future.

Over the past 50 years, vaccination against 14 diseases (diphtheria, Haemophilus influenzae type B, hepatitis B, Japanese encephalitis, measles, meningitis A, pertussis, invasive pneumococcal disease, polio, rotavirus, rubella, tetanus, tuberculosis, and yellow fever) has directly contributed to reducing infant deaths by 40% globally, and by more than 50% in the African Region.

"Vaccines are among the most powerful inventions in history, making once-feared diseases preventable," said WHO Director-General, Dr Tedros Adhanom Ghebreyesus. "Thanks to vaccines, smallpox has been eradicated, polio is on the brink, and with the more recent development of vaccines against diseases like malaria and cervical cancer, we are pushing back the frontiers of disease. With continued research, investment and collaboration, we can save millions more lives today and in the next 50 years."

The study found that for each life saved through immunization, an average of 66 years of full health were gained – with a total of 10.2 billion full health years gained over the five decades. As the result of vaccination against polio more than 20 million people are able to walk today who would otherwise have been paralysed, and the world is on the verge of eradicating polio, once and for all.

These gains in childhood survival highlight the importance of protecting immunization progress in every country of the world and **accelerating efforts to reach the 67 million children who missed out on one or more vaccines during the pandemic years...**

Today, WHO, UNICEF, Gavi, and BMGF are unveiling "**Humanly Possible**", a joint campaign, marking the annual **World Immunization Week, 24-30 April 2024**. The worldwide communication campaign calls on world leaders to advocate, support and fund vaccines and the immunization programmes that deliver these lifesaving products – reaffirming their commitment to public health, while celebrating one of humanity's greatest

achievements. The next 50 years of EPI will require not only reaching the children missing out on vaccines, but protecting grandparents from influenza, mothers from tetanus, adolescents from HPV and everyone from TB, and many other infectious diseases.



"It's inspiring to see what vaccines have made possible over the last fifty years, thanks to the tireless efforts of governments, global partners and health workers to make them more accessible to more people," said Dr Chris Elias, president of Global Development at the Bill & Melinda Gates Foundation. "We cannot let this incredible progress falter. By continuing to invest in immunization, we can ensure that every child – and every person – has the chance to live a healthy and productive life."



Malaria

[World Malaria Day 2024: "Accelerating the fight against malaria for a more equitable world"](#)

Message from Dr Daniel Ngamije, Director of the WHO Global Malaria Programme

24 April 2024

[Excerpt]

...**Since 2017, WHO has reported in the annual World malaria report on a stalling of progress towards critical targets of the global malaria strategy, particularly in countries that carry a high burden of disease.** In 2022, malaria claimed the lives of an estimated 608 000 people worldwide and there were 249 million new cases.

Without a change in the current trajectory, many people, especially those living in situations of greatest poverty and vulnerability, will continue to die from malaria – a disease that is preventable and treatable.

Tackling malaria in high burden countries

Health inequities are hampering efforts to reduce malaria in the countries hardest hit by the disease. Through the "High burden to high impact" (HBHI) approach, catalysed in 2018 by WHO and the RBM Partnership, countries have been tackling malaria by identifying those who suffer most and making a concerted effort to reach them with customized packages of interventions and services.

Last month, Ministers of Health from HBHI countries demonstrated further political commitment by signing the Yaoundé Declaration in which they pledged to accelerate efforts to reduce malaria deaths in their respective countries.

In signing the declaration, Ministers committed to "sustainably and equitably" address the malaria challenge. They recognized the importance of tackling the root causes of stagnating progress in malaria control, including low access to and insufficient quality of health services as well as gender-related and financial barriers within households.

Ministers also committed to the aim of ensuring that all populations at risk of malaria consistently receive the appropriate tools, **including those living in hard-to-reach areas and conflict and humanitarian settings...**

New operational strategy

As you may have seen, **the Global Malaria Programme launched a new operational strategy** ahead of World Malaria Day. The strategy notes that all efforts to fight malaria should be rooted in the principles of health equity, gender equality and human rights to ensure that people in situations of vulnerability are protected and have access to quality health services.

.....

Global Malaria Programme operational strategy 2024-2030

23 April 2024

Overview

As WHO's technical department for malaria, the Global Malaria Programme has an important role to play in leading the global response against this disease. Through its direct actions and network, it has the potential to shape the malaria ecosystem and achieve impact at country level. With this in mind, the Global Malaria Programme has developed an operational strategy outlining its priorities for the period 2024–2030 and the 4 strategic levers to control and eliminate malaria that are decisively within the Programme's mandate: norms and standards, new tools and innovation, strategic information for impact, and leadership. The strategy describes how the Global Malaria Programme will also transform by collaborating more effectively with other programmes, regional and country offices and partners, guided by lessons learned from WHO's Thirteenth General Programme of Work (GPW13) and the GPW14 priorities.

.....

The Lancet

Apr 27, 2024 Volume 403 Number 10437 p1603-1722

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

First-generation malaria vaccine successfully implemented in three African countries

Claudia A Daubenberger, Joana C Silva

Articles

Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi

Kwaku Poku Asante, et al. on behalf of the Malaria Vaccine Programme Evaluation Partners

.....

.....

Meningitis

WHO and France convene high-level meeting to defeat meningitis

Press release

PARIS, 26 APRIL 2024 – Global leaders highlight the need to defeat meningitis – a leading cause of disability – at a high-level meeting co-hosted by the World Health Organization (WHO) and Government of France, under the High Patronage of Emmanuel Macron, President of the French

Republic. **The event is taking place on 26-27 April 2024** at the Institut Pasteur and is supported by prominent athletes advocating on the cause ahead of the Paris Paralympics.

Building on news of Nigeria successfully rolling out a new, safe and highly effective vaccine, which targets five major strains of bacterial meningitis in Africa, leaders committed to implement the global roadmap for “Defeating Meningitis by 2030”, which needs a catalytic investment to action. This groundbreaking plan looks holistically at how to detect, control and beat meningitis in every region of the world, and how to provide rehabilitation to those who have suffered from the deadly disease.

“Bacterial meningitis kills one in six of the people it strikes and leaves one in five with long-lasting disabilities. Yet many of these deaths and disabilities are preventable with vaccines,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. **“Committing to defeat meningitis by 2030 will not only save lives, but will also save billions of dollars in health costs and lost productivity.”**...

This meeting is the first of its kind on meningitis and is co-sponsored by the Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance, the Institut Pasteur and UNICEF. The roadmap is not only about investments for meningitis; it can also have far-reaching implications for primary health care. Its success can accelerate progress in reducing conditions such as sepsis and pneumonia, which are caused by the same bacteria causing meningitis, and can contribute to containing antimicrobial resistance.

There has been significant progress since all Member States approved the roadmap. WHO now aims to fast-track priority research activities, continue updating and developing key strategies and policies, and further support countries in all six WHO regions to develop their national meningitis plans. Further commitments over the coming months will allow for the full implementation of the roadmap initiatives.

.....

[Investing to defeat meningitis and beyond](#)

23 April 2024 | *WHO Technical document* [Download \(4 MB\)](#)

Overview

...Defeating Meningitis by 2030 – A Global Road Map sets out a plan to tackle the main causes of acute bacterial meningitis. This innovative initiative addresses meningitis not only as an infectious disease that can often be prevented and treated, but also with the absolute need for support and care for people living with disabling sequelae after an episode of meningitis. To defeat meningitis resources are required at all levels. The financing needs to implement the road map have been calculated and categorized to maximize the effect of every dollar invested.

Investing in meningitis, will prevent cases of disease, cases of long-lasting sequelae and save lives. Strong multidisciplinary collaborations allowed the road map design to be one that will generate impact beyond meningitis, particularly by combining efforts with other health initiatives at local, national, regional and global levels. Investments called for in this document will strengthen primary health care systems including diagnosis, treatment and care – acting as a powerful lever for recognizing disability and improving access to support and rehabilitation – and providing benefits far beyond meningitis.

All 194 WHO Member States have committed to defeating meningitis by 2030. Now investment is needed to not only reduce the avoidable pain and suffering caused by meningitis but to enable better health outcomes beyond meningitis.



IHR

[Governments near agreement on package of amendments to the International Health Regulations \(2005\)](#)

Historic move makes world better prepared for, and ready to respond to, future public health emergencies

Webcast of WG Sessions

News release 27 April 2024

In the eighth meeting of the Working Group on Amendments to the International Health Regulations (WGIHR), which was suspended yesterday until 16 May, State Parties to the IHR took a major step towards agreeing on the package of amendments which will be put forward to the World Health Assembly, which takes place from 27 May–1 June.

The amendments, proposed by IHR State Parties in the wake of the COVID-19 pandemic to strengthen the international community's ability to detect and respond to pandemic threats, will be **further discussed at the resumed eighth meeting on 16-17 May with a view to finalizing an agreed package for submission to the World Health Assembly in May for its consideration and, if agreed, formal adoption.**

"The International Health Regulations have been the cornerstone of global health security for decades, but the COVID-19 pandemic showed the need to strengthen them in some areas to make them fit for purpose," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Countries are grasping this historic opportunity to protect future generations from the impact of epidemics and pandemics, with a commitment to equity and solidarity."

This eighth meeting of the Working Group on Amendments to the IHR (WGIHR) started on 22 April and suspended today. Whilst the process is being held alongside negotiations of the world's first pandemic agreement to strengthen global collaboration among governments to prepare for, prevent and respond to pandemics, **it was proposed in WGIHR8 that two separate Resolutions on the two processes be submitted to the World Health Assembly in May. Negotiations resume on the pandemic agreement on 29 April and continue until 10 May.**

During the eighth meeting of the WGIHR, substantial progress on finalizing the package of amendments was made as State Parties reached agreement in critical areas.

WGIHR Co-Chair Dr Ashley Bloomfield said: "The work to bolster our global defenses against public health emergencies and risks, through agreeing a stronger set of International Health Regulations, reflects both the risks our highly interconnected world faces today, and the recognition and readiness of countries to ensure their citizens are better protected."

Fellow WGIHR Co-Chair, Dr Abdullah Assiri, said the proposed amendments to the IHR are readily implementable and recognize the importance of equity in ensuring effective global response.

"The COVID-19 pandemic showed the world that viruses of pandemic potential do not respect national borders," Dr Assiri said. "Amending the International Health Regulations reflects the critical need to bolster our collective defenses against current and future public health risks so people's

health, societies and economies can be better protected, all whilst firmly respecting and adhering to the principle of national sovereignty.”

The eighth meeting of the WGHIR will resume in a two-day final session 16-17 May to continue and conclude the work of the Working Group according to its mandate from the Health Assembly.

The IHR have 196 State Parties, comprising all 194 WHO Member States plus Liechtenstein and the Holy See. These Parties have led the process to amend the IHR. The Regulations have been negotiated under Article 21 of the WHO Constitution. Any amendment will come into force for all States Parties, after a set period, except for those that notify the WHO Director-General of a rejection or reservation.

.....

IFPMA Statement

[Eighth Meeting of the Working Group on Amendments to the International Health Regulations \(2005\)](#)

22 Apr 2024

On 22 April 2024, IFPMA delivered a statement at the Eighth Meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva, Switzerland.

This final meeting of the WGIHR is the critical window to ensure that the proposed amendments are workable, fit-for-purpose, and implementable.

It is imperative that Member States and relevant stakeholders have a common understanding of potential solutions and that they are validated for feasibility as early as possible.

We have three key concerns that could lead to uncertainty and would benefit from clear science- and evidence-based criteria to avoid politicization:

- The proposed definitions of “Early Action Alerts,” “Public Health Emergency of International Concern (PHEIC), including a Pandemic Emergency,” and “Pandemics” as well as references to “health products” (including “relevant health products”) are excessively vague. This makes it very difficult for industry to assess the overall instrument.
- The decision-making process to determine and make recommendations on “Early Action Alerts” and “PHEIC, including a Pandemic Emergency” leaves room for discretion and interpretation when it should be based on science- and evidence-based criteria.
- There are recommendations in Article 13 that pre-empt the outcomes of the INB to improve equitable access, in particular the WHO-coordinated mechanisms and networks, and do not strike a balanced approach. It would be premature and potentially counterproductive to include it in IHR.

Before the final hour, amendments must be fully assessed in order to mitigate any risks of potential unintended consequences.


Given the binding nature of the IHR, it is of the utmost importance to course-correct before it is too late. We reiterate our full commitment to this work and remain available to constructively contribute.



Pandemic Accord

[Ninth meeting of the Intergovernmental Negotiating Body \(INB\) for a WHO instrument on pandemic prevention, preparedness and response](#)

WHO Member States will resume INB9 negotiations aimed at finalizing a pandemic agreement during 29 April to 10 May. Beginning April 29, the webcast will be available at this [link](#). No agenda for the first day of the meeting was posted as of 27 April 2024.



[WHO Member States agree to resume negotiations aimed at finalizing the world's first pandemic agreement](#)

28 March 2024 *News release*

The decision came at today's end of two weeks of intensive country-led discussions on critical subjects aimed at making all countries of the world better prepared for, and able to effectively and equitably respond to, future pandemics.

This [ninth meeting](#) of the [Intergovernmental Negotiating Body](#) (INB9) started on 18 March and ended today. Government negotiators discussed all articles from the [draft agreement](#), including adequate financing for pandemic preparedness, equitable access to medical countermeasures needed during pandemics and health workforce strengthening.

"Our Member States are fully aware of how important the pandemic agreement is for protecting future generations from the suffering we endured through the COVID-19 pandemic," said WHO Director-General Dr Tedros Adhanom Ghebreyesus. "I thank them for their clear commitment to finding common ground and finalizing this historic agreement in time for the World Health Assembly."

Next month's resumption of INB9 will be a critical milestone ahead of the Seventy-seventh World Health Assembly, starting 27 May 2024, at which Member States are scheduled to consider the proposed text of the world's first pandemic agreement for adoption...

.....
.....
.....

Polio – PHEIC

[Polio this week as of 24 Apr 2024 - GPEI](#)

Headlines

:: 24-30 April marks World Immunization Week, an opportunity to highlight vaccines as one of humanity's greatest achievements, saving millions of lives every year. This year, World Immunization Week will celebrate 50 years of the Expanded Programme on Immunization (EPI) – a collaborative initiative aimed at ensuring universal access to life-saving vaccines for everyone, everywhere. EPI served as an inspiration for Rotary International to launch PolioPlus in 1985, which led to the founding of the Global Polio Eradication Initiative three years later. The GPEI continues to work with its partners around the world to help strengthen immunization systems everywhere. To mark EPI's 50th anniversary, WHO, UNICEF, Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation are collectively launching 'Humanly Possible', a global campaign to mark the profound achievements of EPI, and to call on leaders to prioritize investments in immunization. A dedicated campaign website, with key data, messages and calls to action went live on 24 April.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: 10 WPV1-positive environmental samples
- Pakistan: two WPV1-positive environmental samples
- Angola: one cVDPV2-positive environmental sample
- Nigeria: two cVDPV2 cases
- Somalia: one cVDPV2 case
- South Sudan: three cVDPV2 cases
- Yemen: one cVDPV2 case and eight positive environmental samples
- Zimbabwe: one cVDPV2-positive environmental sample

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

WHO & Regional Offices [to 27 Apr 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

27 April 2024 *News release*

[Governments near agreement on package of amendments to the International Health Regulations \(2005\)](#)

26 April 2024 *Statement*

[Statement on the antigen composition of COVID-19 vaccines](#)

26 April 2024 *Joint News Release*

[WHO and France convene high-level meeting to defeat meningitis](#)

26 April 2024 *News release*

[WHO reports widespread overuse of antibiotics in patients hospitalized with COVID-19](#)

24 April 2024 *Departmental news*

[World Malaria Day 2024: "Accelerating the fight against malaria for a more equitable world"](#)

24 April 2024 *Joint News Release*

[Global immunization efforts have saved at least 154 million lives over the past 50 years](#)

24 April 2024 *Departmental news*

[In memoriam Dr Riadh Ben-Ismaïl \(1953–2024\)](#)

23 April 2024 *Departmental news*

[WHO Global Malaria Programme launches new operational strategy](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 26 April 2024

[Boosting efforts to transform care for severe chronic diseases in Africa](#)

:: 25 April 2024

[Major step in malaria prevention as three West African countries roll out vaccine](#)

:: 25 April 2024

[Pioneering charter to drive up investment in Africa's health workforce](#)

:: 25 April 2024

[Ghana intensifies efforts towards malaria elimination](#)

WHO Region of the Americas PAHO

:: 25 Apr 2024

[IDB and PAHO Join Forces to Drive Digital Health and Pandemic Preparedness in Latin America and the Caribbean](#)

The new agreement will focus on three priority areas: health systems strengthening based on primary health care; information systems and digital health; and pandemic prevention, preparedness and response. Washington, D.C., 25 April 2024 (PAHO) - The president of the Inter-American Development Bank (IDB), Ilan Goldfajn, and the director of the Pan-

:: 25 Apr 2024

[World Malaria Day – PAHO urges countries to step up access to diagnosis and treatment for vulnerable populations](#)

Washington D.C. 25 April 2024 (PAHO) – With countries of the Americas reporting around 480,000 cases of malaria in 2023, on World Malaria Day, the Pan American Health Organization (PAHO) has

called on governments to step up efforts to tackle the disease, which disproportionately impacts indigenous communities, migrant and other vulnerable...

:: 22 Apr 2024

[PAHO launches Vaccination Week in the Americas 2024](#)

Washington D.C. 22 April 2024 (PAHO) – The 22nd edition of Vaccination Week in the Americas (VWA) 2024 was launched this week under the slogan “Engage now to protect your future #GetVax.” The launch ceremony was led by Pan American Health Organization (PAHO) Director, Dr. Jarbas Barbosa, as well as other high-level health authorities and regional...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 25 April 2024 News release

[Another good reason to vaccinate – to keep life-saving medicines working](#)

:: 22 April 2024 Media release

[COVID-19 Lessons learned: WHO/Europe launches the first Pan-European Network for Disease Control](#)

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

No new digest content identified.

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

25 April 2024

[Triple billion targets policy solutions matrix, updated December 2023](#)

25 April 2024

[Implementation playbook, pocket edition: a quick-reference guide to delivering impact for health, with...](#)

23 April 2024

[Investing to defeat meningitis and beyond](#)

23 April 2024

[Risk communication and community engagement readiness and response toolkit: mpox](#)

23 April 2024

[Global Malaria Programme operational strategy 2024-2030](#)

Overview

As WHO's technical department for malaria, the Global Malaria Programme has an important role to play in leading the global response against this disease. Through its direct actions and network, it has the potential to shape the malaria ecosystem and achieve impact at country level. With this in mind, the Global Malaria Programme has developed an operational strategy outlining its priorities for the period 2024–2030 and the 4 strategic levers to control and eliminate malaria that are decisively within the Programme's mandate: norms and standards, new tools and innovation, strategic information for impact, and leadership. The strategy describes how the Global Malaria Programme will also transform by collaborating more effectively with other programmes, regional and country offices and partners, guided by lessons learned from WHO's Thirteenth General Programme of Work (GPW13) and the GPW14 priorities.

22 April 2024

[Framework for assessing maturity of health accounts institutionalization](#)

22 April 2024

[Joint external evaluation of the International Health Regulations \(2005\) core capacities of Guinea](#)

22 April 2024

[The selection and use of essential medicines \(2023\) - TRS 1049](#)

19 April 2024

[HIV and viral hepatitis diagnostic tests in low- and middle-income countries: forecasts of global and...](#)

.....

.....

USA – HHS, FDA, CDC

HHS

News

No new digest content identified.

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

[Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement - 05/16/2024](#)

CDC/ACIP [U.S.] [to 27 Apr 2024]

<http://www.cdc.gov/media/index.html>

Latest News Releases

No new digest content identified.

ACIP Meetings

Next ACIP Meeting

June 26-28

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

April 25, 2024 / No. 16

[PDF of this issue](#)

- [Use of Ebola Vaccines — Worldwide, 2021–2023](#)
- [SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance — Respiratory Virus Transmission Network, November 2022–May 2023](#)
- [Investigation of Presumptive HIV Transmission Associated with Receipt of Platelet-Rich Plasma Microneedling Facials at a Spa Among Former Spa Clients — New Mexico, 2018–2023](#)
- [Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024](#)

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 22-25 April 2024](#)

EMA's human medicines committee (CHMP) recommended eight medicines for approval at its April 2024 meeting.

26 April 2024

[New recommendations to strengthen supply chains of critical medicines](#)

EMA has published a number of recommendations to address vulnerabilities in the production and delivery of medicines included in the Union list of critical medicines and strengthen their supply chain.

23 April 2024

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[High burden of Hepatitis B and C persists in the EU/EEA](#)

25 Apr 2024

[European Immunization Week 2024](#)

22 Apr 2024

[ECDC reports: vaccine-preventable diseases on the rise in the EU/EEA](#)

22 Apr 2024

In connection with the European Immunization Week, ECDC releases data indicating an increase in cases of vaccine-preventable diseases such as measles and pertussis, after decreased levels during the COVID-19 pandemic.

Dr Andrea Ammon, ECDC Director said: "It is disheartening to see that despite decades of a well-documented safety and effectiveness track record of vaccines, countries in the EU/EEA and globally still face outbreaks of several vaccine-preventable diseases. Achieving and maintaining high vaccination uptake, disease surveillance and prompt response actions to control outbreaks remain the key actions against these diseases. Vaccines have protected many generations, and we should ensure that this continues to be the case"...

.....

.....

Africa CDC [to 27 Apr 2024]

<https://africacdc.org/>

Press Releases, Statements [Selected]

[Africa CDC launches initiatives to advance molecular diagnostics and genomic surveillance in Africa](#)

Addis Ababa, Ethiopia – 24 April 2024 – The Africa Centres for Disease Control and Prevention (Africa CDC) kicked-off two groundbreaking projects: the **Integrated Genomic Surveillance and Data Sharing Platform (IGS) and Integrated Genomic Surveillance for Outbreak Detection (DETECT)**. **These initiatives, co-funded by the European Union**, are poised to fortify the Africa Pathogen Genomics Initiative (Africa PGI 2.0), **enhancing the capacity of member states for molecular detection of outbreaks, AMR genomic surveillance, and timely data sharing across Africa...**

Through these projects implemented by the European Health and Digital Executive Agency (HaDEA), Africa CDC, and HERA, in partnership with African Union (AU) Member States, the African Society for Laboratory Medicine (ASLM) and the Africa Public Health Foundation (APHF), will strengthen national and regional capacities to promptly detect outbreaks, support the integration of AMR genomic surveillance, and facilitate swift and high-quality data sharing for public health decision-making...

Africa CDC's shift towards Africa PGI 2.0 signifies a transition from emergency response to building an optimized, resilient, and integrated molecular diagnostic and genomic surveillance ecosystem. It is critical and timely to incorporate lessons from the COVID-19 pandemic, and empower national and regional reference laboratories to expand their capabilities to detect and characterize epidemic and pandemic-prone diseases. As demonstrated in previous outbreaks, molecular detection and genomic sequencing improves early detection and response to public health emergencies.

Mr. Nqobile Ndlovu, CEO of ASLM, remarked, "The launch of the two projects is pivotal in devising scalable and sustainable approaches **for integrating molecular diagnostics and sequencing within Africa's routine surveillance structures**. We are eager to collaborate with the Africa CDC and HERA to strengthen laboratory systems ensuring effective responses to current and future health threats"...

Press Releases

[Création d'un centre régional de connaissances en Afrique centrale : la plateforme présentée aux experts de la région](#)

22 April 2024

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 27 Apr 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 27 Apr 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

Weekly Reports: Current Volume (6)

2024-04-26 / No. 17 WORLD MALARIA DAY ISSUE

[View PDF of this issue](#)

- [Preplanned Studies: Neglected Time Intervals Before “1-3-7” Approach About Imported Malaria Cases — China, 2014–2021](#)
- [Preplanned Studies: Genome Analysis of Plasmodium falciparum: A Preliminary Observation — Sierra Leone, 2022–2023](#)
- [Vital Surveillances: Situational Analysis of Malaria Incidence Under Integrated Malaria Service in Hotspot Township — Minbya Township, Rakhine State, Myanmar, 2017–2020](#)
- [Vital Surveillances: Cooperative Sentinel Surveillance of Malaria in Laiza and Nearby Areas of Myanmar and Importation Threat Monitoring — China, 2019–2023](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, February 2024*](#)

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 27 Apr 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 27 Apr 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

Press release Apr 24, 2024

[Global immunization efforts have saved at least 154 million lives over the past 50 years](#)

Bill & Melinda Gates Medical Research Institute [to 27 Apr 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 27 Apr 2024]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 27 Apr 2024]

<http://cepi.net/>

Latest News

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 27 Apr 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 27 Apr 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 27 Apr 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 27 Apr 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

25 April 2024

[**World Malaria Day 2024: Accelerating the development of innovative approaches to end malaria**](#)

24 April 2024

[**Medicines for Malaria Venture and Novartis announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria**](#)

Emory Vaccine Center [to 27 Apr 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 27 Apr 2024]

<http://www.euvaccine.eu/>

Latest News, Events

[**World Malaria Day 2024: urgent calls for accelerated global action against malaria**](#)

Malaria poses a significant threat to public health, disproportionately affecting the most vulnerable populations. EVI strengthens the

Evidence Aid [to 27 Apr 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

[**The sexual and reproductive health of migrant children in sub-Saharan Africa**](#)

Added April 21, 2024

Fondation Merieux [to 27 Apr 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 27 Apr 2024]

<https://www.gavi.org/>

Press Releases

26 April 2024

[**WHO and France convene high-level meeting to defeat meningitis**](#)

26 April 2024

[**AUC, Africa CDC, Gavi, the Vaccine Alliance, UNICEF and WHO join the rest of the continent to mark the African Vaccination Week**](#)

25 April 2024

[**Major step in malaria prevention as three West African countries roll out vaccine**](#)

25 April 2024

[**Government of Lao PDR and partners announce campaign to tackle measles and rubella**](#)

24 April 2024

[**Over 50 million lives saved in Africa through expanded immunization programme**](#)

24 April 2024

[**Global immunization efforts have saved at least 154 million lives over the past 50 years**](#)

24 April 2024

[**Madagascar receives a high-level visit from the Global Polio Eradication Initiative \(GPEI\) to strengthen routine immunisation, fight polio, and increase immunisation coverage**](#)

22 April 2024

[**Over 5 million girls in Tanzania to receive HPV vaccine to combat cervical cancer**](#)

GE2P2 Global Foundation [to 27 Apr 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 17 April 2024 – Issue 16](#)

GHIT Fund [to 27 Apr 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 27 Apr 2024]

<https://www.theglobalfund.org/en/news/>

News & Stories

25 April 2024

[**Global Fund Board Welcomes Investments Towards Ending AIDS, Tuberculosis and Malaria; Expresses Concern Over Growing Needs From Polycrisis Amid Global Economic Pressures**](#)

The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) held its 51st meeting this week in Geneva, Switzerland. While anticipating record disbursements this year, with an unprecedented pace of investment in resilient an...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 27 Apr 2024]

<https://www.glopid-r.org/news/>

News

[GloPID-R and STAR-IDAZ take part in the Global One Health international symposium](#)

April 23, 2024

Hilleman Laboratories [to 27 Apr 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 27 Apr 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 27 Apr 2024]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 27 Apr 2024]

<https://www.iavi.org/>

News, Features

IAVI Report April 25, 2024

[Rethinking antibodies for infectious diseases?](#)

The COVID-19 experience, along with lingering manufacturing and delivery concerns, is prompting a harder look at the future of antibody-based treatment and prevention for infectious diseases.

Michael Dumiak

INSERM [to 27 Apr 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 27 Apr 2024]

<https://www.ich.org/page/press-releases>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 27 Apr 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

[ICRC president: "We are witnessing a global and collective failure to protect civilians in armed conflicts"](#)

"Today, from the Democratic Republic of the Congo to Gaza, Sudan, Ukraine and Yemen, we are witnessing a global and collective failure to protect civilians in armed conflicts" says ICRC's president Mirjana Splojaric.

22-04-2024 | Statement

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

[Donors set sights on IFFIm's upcoming role in Gavi replenishment](#)

24 Apr 2024

The Gavi Secretariat and IFFIm Board convened an IFFIm donors' meeting on 25 March to kick off the IFFIm replenishment conversation as part of the overall Gavi 6.0 replenishment ask.

IFRC [to 27 Apr 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 27 Apr 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release

26.04.2024

[WHO and France convene high-level meeting to defeat meningitis](#)

Paralymians join effort to tackle deadly disease Global leaders highlight the need to defeat meningitis – a leading...

ISC / International Science Council [to 27 Apr 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

Blogs

[Strengthening the Voice of Science: Reflections from the Global Knowledge Dialogue in Santiago, Chile](#)

Another fantastic gathering of scientific minds at the Global Knowledge Dialogue for Latin America and the Caribbean

25.04.2024

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 27 Apr 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 27 Apr 2024]

<http://www.ivi.int/>

IVI News & Announcements

[Prof. Jan Holmgren, Profs Barney Graham and Jason McLellan recognized at 2024 IVI-SK bioscience Park MahnHoon Award Ceremony](#)

Johns Hopkins Center for Health Security [to 27 Apr 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 27 Apr 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Madagascar

[Malaria on the rise in Madagascar as climate change leaves healthcare out of reach](#)

Project Update 25 Apr 2024

National Academy of Medicine - USA [to 27 Apr 2024]

<https://nam.edu/programs/>

News [Selected]

[NAM Hosts Convening to Address Research Gaps at the Intersection of Climate Change, Health, and Equity; Leaders Across Disciplines Identify Strategies to Advance Solutions](#)

April 22, 2024

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 27 Apr 2024]

<https://www.nationalacademies.org/newsroom?>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 27 Apr 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

June 13-14, 2024

NIH [to 27 Apr 2024]

<http://www.nih.gov/>

New Releases

[Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen](#)

April 27, 2024 — Study highlights need for defined markers of mpox immunity to inform public health use.

[Experimental NIH malaria monoclonal antibody protective in Malian children](#)

Friday, April 26, 2024 - Mid-stage trial shows treatment prevents infection, disease.

Sabin Vaccine Institute [to 27 Apr 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 27 Apr 2024]

<http://www.unaids.org/en>

News, Stories, Updates

25 April 2024

[How communities led in the HIV response, saving lives in Eswatini at the peak of a crippling AIDS epidemic](#)

UNICEF [to 27 Apr 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Statement 26 April 2024

[UNICEF commends Bhutan for vaccinating almost all children with life-saving vaccines in historic feat](#)

THIMPHU, Bhutan, 26 APRIL 2024 – “UNICEF congratulates the Royal Government of Bhutan for vaccinating almost all eligible children in the country to protect them from deadly diseases.

“According to data released by the Ministry of Health, in 2023, Bhutan vaccinated 99.6 per cent of children under one year with three doses of the pentavalent...

Press release 25 April 2024

[WHO and France convene high-level meeting to defeat meningitis](#)

PARIS, 26 APRIL 2024 – Global leaders highlight the need to defeat meningitis – a leading cause of disability – at a high-level meeting co-hosted by the World Health Organization (WHO) and Government of France, under the High Patronage of Emmanuel Macron, President of the French Republic. The event is taking place on 26-27 April 2024 at the...

Press release 24 April 2024

[Acute hunger remains persistently high in 59 countries with 1 in 5 people assessed in need of critical urgent action - Global Report on Food Crises](#)

ROME/GENEVA/NEW YORK, 24 April 2024 - According to the latest Global Report on Food Crises (GRFC), nearly 282 million people in 59 countries and territories experienced high levels of acute

hunger in 2023 - a worldwide increase of 24 million from the previous year. This rise was due to the report's increased coverage of food crisis contexts as...

Press release 4 April 2024

[Global immunization efforts have saved at least 154 million lives over the past 50 years](#)

GENEVA/NEW YORK/SEATTLE, 24 April 2024 – A major landmark study to be published by The Lancet reveals that global immunization efforts have saved an estimated 154 million lives – or the equivalent of 6 lives every minute of every year – over the past 50 years. The vast majority of lives saved – 101 million – were those of infants. The study, led...

Unitaid [to 27 Apr 2024]

<https://unitaid.org/>

Featured News

25 April 2024

[How Unitaid is supporting Brazil's G20 health agenda with innovative solutions](#)

23 April 2024

[The communities at the heart of malaria prevention in Mozambique](#)

23 April 2024

[New Unitaid report shows manufacturing antimalarials in Africa is critical to fighting malaria](#)

- While Africa shoulders nearly all the world's malaria burden – 95% of deaths and 94% of cases in 2022 were in sub-Saharan Africa – access to quality-assured malaria treatment options remains a significant challenge.
- At the same time, the main WHO-recommended antimalarial treatment – artemisinin-based combination therapy – is losing its effectiveness as the malaria parasite develops resistance.
- A new Unitaid report shows that by strengthening antimalarial manufacturing capacity in Africa and helping to diversify the use of recommended treatments, we can help fight drug resistance and strengthen health security for millions of people at risk of malaria on the continent.

Vaccine Equity Cooperative [nee Initiative] [to 27 Apr 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 27 Apr 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 27 Apr 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 27 Apr 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update for Providers

April 2024

Announcements: New film and screening resources; infectious diseases in a changing world

Wellcome Trust [to 27 Apr 2024]

<https://wellcome.org/>

News, Opinion, Reports

Analysis

Author Charlie Weller

Vaccines have a crucial role in tackling antimicrobial resistance

24 April 2024 3-minute read

Analysis

Author Simge Eva Dogan

Five real-world examples of how climate mitigation can benefit health

23 April 2024 5-minute read

The Wistar Institute [to 27 Apr 2024]

<https://www.wistar.org/news/press-releases>

No new digest content identified.

World Bank [to 27 Apr 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

World Bank Group Aims to Expand Health Services to 1.5 Billion People

Date: April 18, 2024 Type: Factsheet

The World Bank Group announced an ambitious plan to support countries in delivering quality, affordable health services to 1.5 billion people by 2030. This is part of a larger global effort to provide a basic standard of care through every stage of a person's life – infancy, childhood, adolescence, and adulthood.

For decades, the World Bank Group has helped provide health services for women and children in more than 100 countries. A focused effort to become faster, work better with partners, and bring in the private sector has enabled the 80-year-old institution to pursue greater scale and impact.

The strategy to reach 1.5 billion people is focused on three core elements:

:: Expanding focus from maternal and child health to include coverage throughout a person's lifetime, including non-communicable diseases.

:: Expanding operations to hard-to-reach areas, including remote villages, cities, and countries.

:: Working with governments to cut unnecessary fees and other financial barriers to health care.

To be counted toward this goal, a person must be seen and treated by a health-care worker via an in-person visit or telehealth...

WFPHA: World Federation of Public Health Associations [to 27 Apr 2024]

<https://www.wfpha.org/>

Event

No new digest content identified.

World Medical Association [WMA] [to 27 Apr 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [to 27 Apr 2024]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.



ARM [Alliance for Regenerative Medicine] [to 27 Apr 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 27 Apr 2024]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 27 Apr 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 27 Apr 2024]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 27 Apr 2024]

<https://ifpma.org/>

News

Statement 23 Apr 2024

[Fourth meeting of the Intergovernmental Negotiating Committee \(INC-4\) on plastics pollution](#)

On 23 April 2024, IFPMA submitted a statement to the Fourth Meeting of the Intergovernmental Negotiating Committee (INC-4) on plastics pollution in Ottawa, Canada. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) lends its full support to an ambitious UN Global Plastics “Instrument” that can help create globally harmonized rules on plastic.

Statement 22 Apr 2024

[Eighth Meeting of the Working Group on Amendments to the International Health Regulations \(2005\)](#)

On 22 April 2024, IFPMA delivered a statement at the Eighth Meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva, Switzerland.

International Alliance of Patients' Organizations – IAPO [to 27 Apr 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 27 Apr 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest announcements identified.

Bharat Biotech

Press Releases - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac [Bayer Ag – Germany]

News

April 24, 2024

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

- Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat
- Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone
- Avian influenza is latest program progressing to clinical trials under broad infectious disease collaboration agreement with GSK

April 24, 2024

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media - No new digest announcements identified.

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified.

Moderna

Press Releases

April 24, 2024

Moderna and OpenAI Collaborate To Advance mRNA Medicine

- Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients
- Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise

April 22, 2024

Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign

CAMBRIDGE, MA / ACCESSWIRE / April 22, 2024 / Moderna, Inc. today announced a contract with the Ministry of Health in Brazil (Ministério da Saúde) to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19. This contract follows the Brazilian Health Regulatory Agency's (ANVISA) approval of Moderna's COVID-19 vaccine in March 2024, which encodes the spike protein of the XBB.1.5 sublineage of SARS-CoV-2 for active immunization for the prevention of COVID-19 in children from six months of age and adults...

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Apr 24, 2024

- There is currently no evidence-based treatment for the smallest babies with malaria
- The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg
- The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review

Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem® (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety. The trial was conducted in several African countries. The data, which will be presented this week at the Multilateral Initiative on Malaria (MIM Society) 8th Pan-African Malaria Conference in Kigali, have been submitted for regulatory review...

Pfizer

Recent Press Releases - No new digest announcements identified

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

[Press Releases](#) - No new digest announcements identified.

Takeda

[Newsroom](#) - No new digest announcements identified.

Valneva

[Press Releases](#) - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

[Home](#) - Website not responding [404 error]

WestVac Biopharma

[Media](#) - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 4: E275-359 April 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

Global Medical Supply Chain Security

Individual patients' safety and public health were compromised by critical drug shortages, substandard medications, and extremely restricted access to personal protective equipment during the COVID-19 pandemic. As health organizations and workers struggled to meet demands posed by unprecedented patient numbers and illness acuity, our complex global health ecosystem with long-standing upstream supply chain vulnerabilities failed to meet emergent downstream demand in several ways. First, material procurement and ingredient sourcing were inadequate. Second, operations lacking transparency made stopping propagation of substandard or falsified medications ineffective, inefficient, or impossible. Finally, logistical obfuscation made environmental consequences of waste management hard to assess and steward responsibly. Policy makers, health care organizations, regulators, manufacturers, and distributors each have roles in building and maintaining global medical supply chain security. This theme issue investigates how these and other agents' failures to cultivate public health capacity, nourish sustainable production processes, and carefully maintain systemic supply chain resiliency are neither accidental nor simply unfortunate, but unjust.

American Journal of Human Genetics

Apr 04, 2024 Volume 111 Issue 4 p621-806

<https://www.cell.com/ajhg/current>

[Reviewed earlier]

American Journal of Infection Control

April 2024 Volume 52 Issue 4p 381-499

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

April 2024 Volume 66 Issue 4p 573-750

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

May 2024 114(5)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 4 (Apr 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/4/tpmd.110.issue-4.xml>

[Reviewed earlier]

Annals of Internal Medicine

April 2024 Volume 177, Issue 4

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 330 May 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/330/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 27 Apr 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 27 Apr 2024)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 27 Apr 2024)

[Herpes zoster \(HZ\) vaccine coverage and confidence in Italy: a Nationwide cross-sectional study, the OBVIOUS project](#)

Herpes Zoster is an age dependent disease and as such it represents a problem in the Italian social context, where the demographic curve is characterized by an overrepresentation of the elderly population. Vac...

Authors: Aurelia Salussolia, Angelo Capodici, Francesca Scognamiglio, Giusy La Fauci, Giorgia Soldà, Marco Montalti, Zeno Di Valerio, Maria Pia Fantini, Anna Odone, Claudio Costantino, Heidi J. Larson, Julie Leask, Jacopo Lenzi and Davide Gori

Citation: BMC Infectious Diseases 2024 24:438

Content type: Research Published on: 24 April 2024

[Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination](#)

Studies have shown that Omicron breakthrough infections can occur at higher SARS-CoV-2 antibody levels compared to previous variants. Estimating the magnitude of immunological protection induced from COVID-19 ...

Authors: Alexander Hönning, Sara Tomczyk, Julia Hermes, Marica Grossegeesse, Natalie Hofmann, Janine Michel, Markus Neumann, Andreas Nitsche, Berthold Hoppe, Tim Eckmanns, Hajo Schmidt-Traub and Kristina Zappel

Citation: BMC Infectious Diseases 2024 24:436

Content type: Research Published on: 24 April 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 27 Apr 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 27 Apr 2024)

[A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial](#)

The stalling global progress in malaria control highlights the need for novel tools for malaria elimination, including transmission-blocking vaccines. Transmission-blocking vaccines aim to induce human antibody...

Authors: M. Alkema, M. J. Smit, C. Marin-Mogollon, K. Totté, K. Teelen, G. J. van Gemert, M. van de Vegte-Bolmer, B. G. Mordmüller, J. M. Reimer, K. L. Lövgren-Bengtsson, R. W. Sauerwein, T. Bousema, J. Plieskatt, M. Theisen, M. M. Jore and M. B. B. McCall

Citation: BMC Medicine 2024 22:170

Content type: Research article Published on: 23 April 2024

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 27 Apr 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 27 Apr 2024)

[The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium \(2020-2022\)](#)

When formulating and evaluating COVID-19 vaccination strategies, an emphasis has been placed on preventing severe disease that overburdens healthcare systems and leads to mortality. However, more conventional ...

Authors: Lander Willem, Steven Abrams, Nicolas Franco, Pietro Coletti, Pieter J. K. Libin, James Wambua, Simon Couvreur, Emmanuel André, Tom Wenseleers, Zhuxin Mao, Andrea Torneri, Christel Faes, Philippe Beutels and Niel Hens

Citation: BMC Public Health 2024 24:1171

Content type: Research Published on: 26 April 2024

[Understanding the factors associated with COVID-19 vaccine hesitancy in Venezuela](#)

Despite nearly a quarter of Venezuelans remaining unvaccinated against coronavirus disease 2019 (COVID-19), the factors contributing to vaccine hesitancy in the country have not been thoroughly investigated.

Authors: Fabián R. Chacón-Labrador, María G. Passantino, Augusto Moncada-Ortega, Atahualpa A. Ávila, Andrea A. Moreno, Nicolle A. Kuffaty-Akkou, Luisana M. Pedroza, Natasha A. Camejo-Ávila, Daniela L. Mendoza-Millán, Carlis M. Rodríguez-Saavedra, María V. Marcano-Rojas, Fernando Hernández-Medina, María E. Grillet, Fhabían S. Carrión-Nessi and David A. Forero-Peña

Citation: BMC Public Health 2024 24:1117

Content type: Research Published on: 23 April 2024

[An evaluation of physical access barriers to COVID-19 vaccines uptake among persons with physical disabilities in western Kenya](#)

Physically disabled persons continue to be discriminated, excluded and neglected based on design of structures and their location. This hampers equitable access to services and disproportionately affect them d...

Authors: David Omondi Odongo, Esther Osir and Shehu Shagari Awandu

Citation: BMC Public Health 2024 24:1112

Content type: Research Published on: 22 April 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 27 Apr 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

April 2024 - Volume 29 - 2

<https://ebm.bmj.com/content/29/2>

[Reviewed earlier]

BMJ Global Health

April 2024 - Volume 9 - Suppl 1

https://gh.bmj.com/content/9/Suppl_1

Social determinants of health equity

[Reviewed earlier]

Bulletin of the Atomic Scientists

March 2024

<https://thebulletin.org/magazine/2024-03/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(4); 2024 Apr 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/458786/>

[Reviewed earlier]

Cell

Apr 25, 2024 Volume 187 Issue 9 p2029-2342

<https://www.cell.com/cell/current>

50th Anniversary

[Immunology is for everyone](#)

The Cell editorial team

This "Focus on Immunology" issue brings Cell's 50th anniversary celebrations straight to your lymph nodes! Special Leading Edge articles highlight the exciting past, present, and future

[From periphery to center stage: 50 years of advancements in innate immunity](#)

Susan Carpenter, Luke A.J. O'Neill

Open Access

Understanding of innate immunity has expanded enormously in recent history. In light of Cell's 50th anniversary, this review traces the development of the innate immunity field from the 1970s through today, highlighting how advances in knowledge now lead to therapeutic strategies.

Featured Article

Principles and therapeutic applications of adaptive immunity

Hongbo Chi, Marion Pepper, Paul G. Thomas

Open Access

The processes of adaptive immunity are central to both health and disease. This review presents a comprehensive yet straightforward overview of lymphocyte biology, homing in on how understanding adaptive immunity holds the key to therapies and future discoveries.

Exploring new perspectives in immunology

Ruslan Medzhitov, Akiko Iwasaki

Despite deep knowledge of how the immune system works, many questions remain difficult to answer within the current core framework of innate and adaptive immunity. This perspective highlights open questions where a change in the conceptual approach could be transformative for addressing persistent challenges to human health.

The plant immune system: From discovery to deployment

Jonathan D.G. Jones, Brian J. Staskawicz, Jeffery L. Dangl

Open Access

Plant diseases significantly impact human and environmental health. This review encompasses the last 50 years of research in the plant immune system, an overview of the pathogen virulence proteins, and strategies for durable resistance.

Many paths lead to immunology

Ana J. García-Sáez, Ana I. Domingos, J. Silvio Gutkind, Seema Mattoo,

Peng Du

While some people pore over the textbook and train through the classics of the field, many scientists come to immunology when they discover it intersecting with their “first love” interests. Five of these “accidental immunologists” tell us how they found their way to a fascination with the immune system.

Creating connections when we talk about science

For Cell’s 50th anniversary Focus on Immunology, scientific editor Cheri Sirois asked science communicator Liz Neeley, founding partner of Liminal and cofounder of Solving for Science, to discuss strategies for tackling technical complexity and for engaging effectively with broad audiences. A lightly edited transcript of their conversation is shared here.

Child Care, Health and Development

Volume 50, Issue 3 May 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 5 Pages: 907-1175 May 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

March 2024 Volume 46 Issue 3 p185-304

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 21 Issue 2, April 2024

<https://journals.sagepub.com/toc/ctja/21/2>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 27 Apr 2024]

[No new digest content identified]

Contemporary Clinical Trials

Volume 138 March 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/1387/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 2 / April 2024

<https://www.liebertpub.com/toc/crispr/7/2>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 3 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

April 2024 - Volume 37 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 27 Apr 2024]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 2 Pages: 49-134 June 2024
<https://onlinelibrary.wiley.com/toc/14718847/current>
ORIGINAL ARTICLES

[Extreme poverty first: An argument on the equitable distribution of the COVID-19 vaccine in Peru](#)

Carlos Augusto Yabar

Pages: 97-101

First Published: 03 February 2023

Development in Practice

Volume 34, Issue 2, 2024

<https://www.tandfonline.com/toc/cdip20/34/2>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 3 May 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[[New issue; No digest content identified]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 2 April 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/2>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 4 20 April 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 4—April 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 46 March 2024

<https://www.sciencedirect.com/journal/epidemics/vol/46/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 2 Pages: 1-35 March–April 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Indigenous data sovereignty :: Returning clinically relevant results

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 2, April 2024

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

March/April 2024 Volume 103, Number 2

<https://www.foreignaffairs.com/issues/2023/103/2>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

Article

[The Relationship Between Health aid and Health Outcomes and the Role of Domestic Healthcare Expenditure in Developing Countries](#)

Isabelle Leunig, Geske Dijkstra & Pieter Tuytens

Pages: 211-234

Published online: 22 Mar 2024

Genetics in Medicines

Volume 26, Issue 4 April 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/4>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 27 Apr 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 1 February 28, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 27 Apr 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 27 Apr 2024]

[Harnessing the potential of African youth for transforming health research in Africa](#)

Authors: Yusuff Adebayo Adebisi, Nafisat Dasola Jimoh, Archibong Edem Bassey, Hassan Olayemi Alaka, Mohamed Marah, Chimwemwe Ngoma, Isaac Olushola Ogunkola, Oumnia Bouaddi, Idahor Courage, Radwa Abdalla Abdelatif El-Abasiri, Rime Boutahar, Molly Unoh Ogbodum, Aniekan Michael Ekpenyong, Theogene Uwizeyimana, Oviri Edith Oghenerukevwe and David Bamidele Olawade

Content type: Commentary 25 April 2024

Abstract

Africa faces a significant burden of infectious diseases, including Malaria and HIV/AIDS, along with an increasing prevalence of non-infectious diseases such as diabetes and cancer. This dual health

challenge is amplified by socioeconomic difficulties, restricted access to healthcare, and lifestyle changes, thus present unique scientific needs. Effectively addressing these issues requires a skilled scientific workforce adept in comprehensive healthcare strategies. This analysis explores the critical landscape of health research in Africa, emphasizing the unique opportunity presented by the continent's youthful population, projected to reach almost 1 billion by 2050. The youth's innovative potential and fresh perspectives offer a chance to overcome development barriers in health research. Nevertheless, challenges such as under-resourced education, limited research training, inadequate mentorship, and funding difficulties persist. This paper urgently calls upon African leaders, international partners, and stakeholders to prioritize health research, mobilize funding, forge strategic partnerships, and empower the youth as essential steps to capitalize on the continent's dynamic youth for breakthrough health outcomes. Such investments are vital not just for health but for the overall economic, social, and strategic growth of the continent. Through shared responsibility and a united effort, the potential of African youth can be harnessed, leading to transformative research, improved health outcomes, and a prosperous future. This perspective represents the collective voice of passionate young researchers and advocates across Africa, calling for a new era of health research on the continent.

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 3, April 2024

<https://academic.oup.com/heapol/issue/39/3>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 27 Apr 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 7-8 / April 2024

<https://www.liebertpub.com/toc/hum/35/7-8>

Review

[The New Frontiers of Gene Therapy and Gene Editing in Inflammatory Diseases](#)

[Alessandro Romano](#) and [Alessandra Mortellaro](#)

Pages:219–231

Published Online:12 March 2024

<https://doi.org/10.1089/hum.2023.210>

Abstract

Inflammatory diseases are conditions characterized by abnormal and often excessive immune responses, leading to tissue and organ inflammation. The complexity of these disorders arises from the intricate interplay of genetic factors and immune responses, which challenges conventional therapeutic approaches. However, the field of genetic manipulation has sparked unprecedented optimism in addressing these complex disorders. This review aims to comprehensively explore the application of gene therapy and gene editing in the context of inflammatory diseases, offering solutions that range from correcting genetic defects to precise immune modulation. These therapies have exhibited remarkable potential in ameliorating symptoms, improving quality of life, and even achieving disease remission. As we delve into recent breakthroughs and therapeutic applications, we illustrate how these advancements offer novel and transformative solutions for conditions that have traditionally eluded conventional treatments. By examining successful case studies and preclinical research, we emphasize the favorable results and substantial transformative impacts that gene-based interventions have demonstrated in patients and animal models of inflammatory diseases such as chronic granulomatous disease, cryopyrin-associated syndromes, and adenosine deaminase 2 deficiency, as well as those of multifactorial origins such as arthropathies (osteoarthritis, rheumatoid arthritis) and inflammatory bowel disease. In conclusion, gene therapy and gene editing offer transformative opportunities to address the underlying causes of inflammatory diseases, ushering in a new era of precision medicine and providing hope for personalized, targeted treatments.

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[**Lessons learned during the height of the Covid-19 pandemic: localisation is the key to programme adaptation during shocks**](#)

Article

April 22, 2024

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

Immunity

Mar 12, 2024 Volume 57 Issue 3 p401-612

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 27 Apr 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 27 Apr 2024]
[No new digest content identified]

International Health

Volume 16, Issue 2, March 2024
<https://academic.oup.com/inthealth/issue/16/2>
[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)
<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 3 (2024): March 2024
<https://www.ijcmph.com/index.php/ijcmph/issue/view/110>
[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 2, April 2024
<https://academic.oup.com/ije/issue/53/2>
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>
Table of contents
[Reviewed earlier]

JAMA

April 23/30, 2024, Vol 331, No. 16, Pages 1343-1426
<https://jamanetwork.com/journals/jama/currentissue>
[New issue; No digest content identified]

JAMA Health Forum

April 2024, Vol 5, No. 4
<https://jamanetwork.com/journals/jama-health-forum/issue>
[Reviewed earlier]

JAMA Pediatrics

April 2024, Vol 178, No. 4, Pages 326-422
<https://jamanetwork.com/journals/jamapediatrics/currentissue>
[Reviewed earlier]

JBI Evidence Synthesis

March 2024 - Volume 22 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

April 2024 Volume 74 Issue 4 p629-860

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 2 April 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-2>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 168 May 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/168/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 1-2, February–April 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

March 2024 - Volume 78 - 3

<https://jech.bmj.com/content/78/3>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 1 Pages: 1-235 March 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 1, February 2024

<https://muse.jhu.edu/issue/52063>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 2 April 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-2>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 229, Issue 3, 15 March 2024

<https://academic.oup.com/jid/issue/229/3>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 3 Pages: 3-1943 April 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

April 2024 - Volume 50 - 4

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 1 (2024)
<https://institutionalrepository.aah.org/jpcrr/>
[Reviewed earlier]

The Journal of Pediatrics

Volume 267 April 2024
<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/267/suppl/C>
[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1
<https://www.tandfonline.com/toc/jppp20/17/1>
[Reviewed earlier]

Journal of Public Health Management & Practice

March/April 2024 - Volume 30 - Issue 2
<https://onlinelibrary.wiley.com/toc/10991328/current>
[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 1, March 2024
<https://link.springer.com/journal/41271/volumes-and-issues/45-1>
[Reviewed earlier]

Journal of the Royal Society – Interface

April 2024 Volume 21 Issue 213
<https://royalsocietypublishing.org/toc/rsif/current>
[Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 3 April 2024
<https://academic.oup.com/jtm/issue>
[Reviewed earlier]

Journal of Virology

Volume 98 • Number 2 • February 2024
<http://jvi.asm.org/content/current>
[Reviewed earlier]

The Lancet

Apr 27, 2024 Volume 403 Number 10437 p1603-1722
<https://www.thelancet.com/journals/lancet/issue/current>
Comment

[**First-generation malaria vaccine successfully implemented in three African countries**](#)

Articles

[Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi](#)

Kwaku Poku Asante, et al. on behalf of the Malaria Vaccine Programme Evaluation Partners

Summary

Background

The RTS,S/AS01E malaria vaccine (RTS,S) was introduced by national immunisation programmes in Ghana, Kenya, and Malawi in 2019 in large-scale pilot schemes. We aimed to address questions about feasibility and impact, and to assess safety signals that had been observed in the phase 3 trial that included an excess of meningitis and cerebral malaria cases in RTS,S recipients, and the possibility of an excess of deaths among girls who received RTS,S than in controls, to inform decisions about wider use.

Methods

In this prospective evaluation, 158 geographical clusters (66 districts in Ghana; 46 sub-counties in Kenya; and 46 groups of immunisation clinic catchment areas in Malawi) were randomly assigned to early or delayed introduction of RTS,S, with three doses to be administered between the ages of 5 months and 9 months and a fourth dose at the age of approximately 2 years. Primary outcomes of the evaluation, planned over 4 years, were mortality from all causes except injury (impact), hospital admission with severe malaria (impact), hospital admission with meningitis or cerebral malaria (safety), deaths in girls compared with boys (safety), and vaccination coverage (feasibility). Mortality was monitored in children aged 1–59 months throughout the pilot areas. Surveillance for meningitis and severe malaria was established in eight sentinel hospitals in Ghana, six in Kenya, and four in Malawi. Vaccine uptake was measured in surveys of children aged 12–23 months about 18 months after vaccine introduction. We estimated that sufficient data would have accrued after 24 months to evaluate each of the safety signals and the impact on severe malaria in a pooled analysis of the data from the three countries. We estimated incidence rate ratios (IRRs) by comparing the ratio of the number of events in children age-eligible to have received at least one dose of the vaccine (for safety outcomes), or age-eligible to have received three doses (for impact outcomes), to that in non-eligible age groups in implementation areas with the equivalent ratio in comparison areas. To establish whether there was evidence of a difference between girls and boys in the vaccine's impact on mortality, the female-to-male mortality ratio in age groups eligible to receive the vaccine (relative to the ratio in non-eligible children) was compared between implementation and comparison areas. Preliminary findings contributed to WHO's recommendation in 2021 for widespread use of RTS,S in areas of moderate-to-high malaria transmission.

Findings

By April 30, 2021, 652 673 children had received at least one dose of RTS,S and 494 745 children had received three doses. Coverage of the first dose was 76% in Ghana, 79% in Kenya, and 73% in Malawi, and coverage of the third dose was 66% in Ghana, 62% in Kenya, and 62% in Malawi. 26 285 children aged 1–59 months were admitted to sentinel hospitals and 13 198 deaths were reported through mortality surveillance. Among children eligible to have received at least one dose of RTS,S, there was no evidence of an excess of meningitis or cerebral malaria cases in implementation areas compared with comparison areas (hospital admission with meningitis: IRR 0·63 [95% CI 0·22–1·79]; hospital admission with cerebral malaria: IRR 1·03 [95% CI 0·61–1·74]). The impact of RTS,S introduction on mortality was similar for girls and boys (relative mortality ratio 1·03 [95% CI 0·88–1·21]). Among children eligible for three vaccine doses, RTS,S introduction was associated with a 32% reduction (95% CI 5–51%) in hospital admission with severe malaria, and a 9% reduction (95% CI 0–18%) in all-cause mortality (excluding injury).

Interpretation

In the first 2 years of implementation of RTS,S, the three primary doses were effectively deployed through national immunisation programmes. There was no evidence of the safety signals that had been observed in the phase 3 trial, and introduction of the vaccine was associated with substantial reductions in hospital admission with severe malaria. Evaluation continues to assess the impact of four doses of RTS,S.

Funding

Gavi, the Vaccine Alliance; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and Unitaid.

The Lancet Child & Adolescent Health

May 2024 Volume 8 Number 5 p311-384

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Apr 2024 Volume 6 Number 4 e230-e298

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

May 2024 Volume 12 Number 5 e712-e890

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Apr 2024 Volume 24 Number 4 p329-436, e207-e267

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Apr 2024 Volume 9 Number 4 e207-e274

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Apr 2024 Volume 12 Number 4 p255-336, e13-e30

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 5 May 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-5>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 3, April 2024
<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 102, Issue 1 Pages: 1-269 March 2024
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Apr 03, 2024 Volume 32 Issue 4 p857-1178
<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 628 Issue 8009, 25 April 2024
<https://www.nature.com/nature/volumes/627/issues/8009>
[New issue; No digest content identified]

Nature Biotechnology

Volume 42 Issue 4, April 2024
<https://www.nature.com/nbt/volumes/42/issues/4>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 27 Apr 2024)
[No new digest content identified]

Nature Genetics

Volume 56 Issue 4, April 2024
<https://www.nature.com/ng/volumes/56/issues/4>
[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 4, April 2024
<https://www.nature.com/nathumbehav/volumes/8/issues/4>
Feature 04 Mar 2024

[Science communication with generative AI](#)

Generative AI tools can quickly translate or summarize large volumes of complex information. This technology could revolutionize the way that we communicate science, but there are many reasons for caution. We asked six experts about the potential and pitfalls of generative AI for science communication.

Amanda Alvarez, Aylin Caliskan, Jevin West

Nature Medicine

Volume 30 Issue 4, April 2024

<https://www.nature.com/nm/volumes/30/issues/4>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 4, April 2024

<https://www.nature.com/nrd/volumes/23/issues/4>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 4, April 2024

<https://www.nature.com/nrg/volumes/25/issues/4>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 4, April 2024

<https://www.nature.com/nri/volumes/24/issues/4>

[Reviewed earlier]

New England Journal of Medicine

Volume 390 No. 16 April 25, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 3 No. 4 April 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

npj Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 27 Apr 2024]

Comment Open access

Published: 13 April 2024

[**The role of correlates of protection in overcoming barriers to vaccine development and demonstrating efficacy**](#)

[Deborah F. King, Helen Groves & Charlotte Weller](#)

[npj Vaccines volume 9, Article number: 78 \(2024\)](#)

Pediatrics

Volume 153, Issue 4 April 2024

<https://publications.aap.org/pediatrics/issue/153/4>

[Reviewed earlier]

Pharmacoeconomics

Volume 42, Issue 4 April 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-4>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 27 Apr 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 27 Apr 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 27 Apr 2024)

[Infection-related severe maternal outcomes and case fatality rates in 43 low and middle-income countries across the WHO regions: Results from the Global Maternal Sepsis Study \(GLOSS\)](#)

Adama Baguiya, Mercedes Bonet, Vanessa Brizuela, Cristina Cuesta, Marian Knight, Pisake Lumbiganon, Edgardo Abalos, Séni Kouanda, WHO Global Maternal Sepsis Study Research Group
Research Article | published 25 Apr 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003109>

[Decolonising global health research: Shifting power for transformative change](#)

Ramya Kumar, Rajat Khosla, David McCoy

Review | published 24 Apr 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003141>

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 27 Apr 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 27 Apr 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 27 Apr 2024]

[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 27 Apr 2024]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

April 23, 2024 vol. 121 no. 17

<https://www.pnas.org/toc/pnas/121/17>

Population Biology

Research Article April 17, 2024 Coronavirus (COVID-19)

[Inferring COVID-19 testing and vaccination behavior from New Jersey testing data](#)

Characterizing the relationship between disease testing behaviors and infectious disease dynamics is of great importance for public health. Tests for both current and past infection can influence disease-related behaviors at the individual level, while ...

Ari S. Freedman, Justin K. Sheen, [...] C. Jessica E. Metcalf

PNAS Nexus

Volume 3, Issue 3, March 2024

<https://academic.oup.com/pnasnexus/issue/3/3>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

Systematic Review

[Quantitative Metrics in Mass-Gathering Studies: A Comprehensive Systematic Review](#)

Cüneyt Çalışkan, Ahmet Doğan Kудay, Tuğba Özcan, Nihal Dağ, Kerem Kınık

Published online by Cambridge University Press:

05 April 2024, pp. 195-205

Preventive Medicine

Volume 181 April 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/181/suppl/C>

[New issue; No digest content identified]

Proceedings of the Royal Society B

30 April 2024 Volume 291 Issue 2021

<https://royalsocietypublishing.org/toc/rspb/current>

Biological science practices

[**A practical guide to cross-cultural and multi-sited data collection in the biological and behavioural sciences**](#)

Laure Spake, ... See all authors

Published: 24 April 2024 Article ID: 20231422

<https://doi.org/10.1098/rspb.2023.1422>

Abstract

Researchers in the biological and behavioural sciences are increasingly conducting collaborative, multi-sited projects to address how phenomena vary across ecologies. These types of projects, however, pose additional workflow challenges beyond those typically encountered in single-sited projects. Through specific attention to cross-cultural research projects, we highlight four key aspects of multi-sited projects that must be considered during the design phase to ensure success: (1) project and team management; (2) protocol and instrument development; (3) data management and documentation; and (4) equitable and collaborative practices. Our recommendations are supported by examples from our experiences collaborating on the Evolutionary Demography of Religion project, a mixed-methods project collecting data across five countries in collaboration with research partners in each host country. To existing discourse, we contribute new recommendations around team and project management, introduce practical recommendations for exploring the validity of instruments through qualitative techniques during piloting, highlight the importance of good documentation at all steps of the project, and demonstrate how data management workflows can be strengthened through open science practices. While this project was rooted in cross-cultural human behavioural ecology and evolutionary anthropology, lessons learned from this project are applicable to multi-sited research across the biological and behavioural sciences.

Public Health

Volume 229 Pages 1-200 (April 2024)

<https://www.sciencedirect.com/journal/public-health/vol/229/suppl/C>

Research article Abstract only

[**Child and adolescent COVID-19 vaccination coverage by educational setting, United States**](#)

K.H. Nguyen, C. McChesney, C. Rodriguez, L. Vasudevan, ... L. Corlin

Pages 126-134

Short communication Abstract only

[**COVID-19 vaccination roll-out and uptake among refugees and migrants in Greece: a retrospective analysis of national vaccination routine data**](#)

K.P. Puchner, V. Giannakou, A. Veizis, K. Bougioukas, ... E. Kondilis

Pages 84-87

Public Health Ethics

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 2, March/April 2024

<https://journals.sagepub.com/toc/phrg/139/2>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 5, April 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 20 Issue 2, April 2024

<http://journals.sagepub.com/toc/reab/current>

Special collection: Research Integrity and Research Misconduct

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 27 Apr 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

[No new digest content identified]

Risk Analysis

Volume 44, Issue 5 Pages: 1007-1267 May 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 27 Apr 2024]

Original Research

[Pharmacy-Based Influenza Vaccination: A Study of Patient Acceptance in Romania](#)

Chirila S, Hangan T, Gurgas L, Costache MG, Vlad MA, Nitu BF, Bittar SM, Craciun A, Condur L, Bjørklund G

Risk Management and Healthcare Policy 2024, 17:1005-1013

Published Date: 24 April 2024

Science

Volume 384| Issue 6694| 26 Apr 2024

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 30, Issue 2 April 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-2>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 744| 24 Apr 2024

<https://www.science.org/toc/stm/current>

Research Articles

[Antigenic distance between primary and secondary dengue infections correlates with disease risk](#)

BY Lin Wang, et al.

24 Apr 2024

Antigenic distance between primary and secondary dengue virus infections is associated with dengue disease risk.

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 27 Apr 2024]

[No new digest content identified]

Social Science & Medicine

Volume 346 April 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/346/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 27 Apr 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 2 April 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-2>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 58 March–April 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/58/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 4 Pages: i-iv, 257-342 April 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 11 Pages 2729-2932 (19 April 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/11>

Selected Content

Research article Open access

[The influence of health service interactions and local policies on vaccination decision-making in immigrant women: A multi-site Canadian qualitative study](#)

Stephanie P. Brooks, Kamaljit Sidhu, Elizabeth Cooper, S. Michelle Driedger, ... Cynthia G. Jardine
Pages 2793-2800

Research article Abstract only

[Effect of age at initiation of the human papillomavirus vaccine on the association between race/ethnicity and completion of the vaccine series](#)

Jacqueline Hirth, Tiffany Ostovar-Kermani, Judith A. Gutierrez, Erika L. Thompson, ... Roger Zoorob
Pages 2827-2836

Research article Open access

[Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh](#)

Christopher Weyant, Yogesh Hooda, Sira Jam Munira, Nathan C. Lo, ... Jason R. Andrews
Pages 2867-2876

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 27 Apr 2024]

Open Access Article

[The Impact of the Coronavirus Pandemic on Vaccination Coverage in Latin America and the Caribbean](#)

by Ignacio E. Castro-Aguirre, Dan Alvarez, Marcela Contreras, Silas P. Trumbo, Oscar J. Mujica, Daniel Salas Peraza and Martha Velandia-González

Vaccines 2024, 12(5), 458; <https://doi.org/10.3390/vaccines12050458> - 25 Apr 2024

Abstract

Background: Routine vaccination coverage in Latin America and the Caribbean declined prior to and during the coronavirus pandemic. We assessed the pandemic's impact on national coverage levels and analyzed whether financial and inequality indicators, immunization policies, and pandemic policies were associated with changes [...] [Read more.](#)

Value in Health

April 2024 Volume 27 Issue 4 p383-542

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 176 April 2024

<https://www.sciencedirect.com/journal/world-development/vol/176/suppl/C>

[Reviewed earlier]



Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)



Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 27 Apr 2024]

Selected Research

Research Article metrics AWAITING PEER REVIEW

[Health care-seeking behavior for childhood illnesses in western Kenya: Qualitative findings from the Child Health and Mortality Prevention Surveillance \(CHAMPS\) Study](#)

[version 1; peer review: awaiting peer review]

Sarah Ngere, Maria Maixenchs, Sammy Khagayi, Peter Otieno, Kennedy Ochola, Kelvin Akoth, Aggrey Igunza, Benard Ochieng, Dickens Onyango, Victor Akelo, John Blevins, Beth A. Tippet Barr
Peer Reviewers Invited

Funder

Bill and Melinda Gates Foundation

PUBLISHED 24 Apr 2024

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 27 Apr 2024]

[Filter: All articles]

[Website stopped responding mid-session]

[The potential role of cultural and religious healing practices in shaping community vulnerability to highly infectious diseases in western Kenya](#)

Naomi Wambui Nganga, Reuben Onkoba Momanyi, Caleb Chemirmir, Hazael Biwott, George Ayodo, Monica Orero, Damaris Ochanda, Sarah Ngere, Winnie Ogola, Titus Murundu, Geoffrey Munene, Zachary Misiani, Michael Ayaibei, Richard Dimba Kiaka

medRxiv 2024.04.24.24306297; doi: <https://doi.org/10.1101/2024.04.24.24306297>

Abstract

We draw from empirical research conducted in communities in three border counties in western Kenya – Homa Bay, Bungoma and West Pokot - to examine how cultural and religious beliefs and healing practices can potentially shape the vulnerability of those communities to highly infectious diseases. Fieldwork consisting of mixed methods namely, key informant interviews with traditional and religious healers as well as their patients, focus group discussions with community members knowledgeable on cultural customs and practices, and participatory inquiry workshops with health professionals and administrators were used to collect the data. We find that traditional and religious

beliefs and healing practices potentially shape community vulnerability to highly infectious diseases in two major ways. First, is a dualistic illness etiology involving a biomedical and socio-cultural etiology. Unexplained illnesses and illnesses that did not respond to conventional medicine were treated using traditional medicine. Making traditional and religious healers the first mile treatment preference could potentially delay appropriate treatment and compromise safe handling in case the disease is highly infectious. Second aspect pertains to the risks in the traditional and spiritual healing practices. Shared consecrated water often fetched from a large water body, laying of hands, use of herbs and rituals involving slaughtering of animals enhanced contacts. The use of protective gears during healing was inconsistent among the healers, but largely lacking as many healers could not afford them or were considered to reduce patient's faith in the healing powers. These practices potentially predispose people to highly infectious diseases and can hasten the spread and symptom severity. To reduce the vulnerability of border communities to highly infectious diseases, we argue for a need for comprehensive strategies that consider the intersecting factors of vulnerability to outbreaks, healing beliefs and practices. This may involve policy initiatives aimed at integrating traditional medicine practice and the mainstream health system.

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[MEDICAL ETHICS AND FACILITATING FULLY INFORMED CONSENT TO TREATMENT](#)

Date created: 2024-04-23 Date modified: 2024-04-23

preprint DOI - <https://doi.org/10.31219/osf.io/7b64n>

Authors: [Alan Mordue](#), [Evans E A](#), [Royle T J](#), and [Clare Craig](#)

Abstract

It has been asserted that there was an erosion of medical ethics during the Covid-19 pandemic and a departure from the principle of obtaining fully informed consent from patients before treatment. In light of these assertions, this article reviews the historical development of medical ethics and the approach to obtaining informed consent, and critiques the consent practices before and during the pandemic. It then describes a new tool for displaying key statistics on the benefits and risks of interventions to help explain them to patients and suggests a more rigorous process for seeking fully informed consent in the future.

[Research Transparency in 59 Disciplines of Clinical Medicine: A Meta-Research Study](#)

[Eero Raittio](#), [Dena Zeraatkar](#), [Lex Bouter](#), [Sergio E Uribe](#), [Sahar Khademioore](#), and 3 more

Date created: 2024-04-22 Date modified: 2024-04-22

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 27 Apr 2024]

Selected Research

Research Note Open Access

[Recruitment strategies used to enrol healthy volunteers in the first pneumococcal human infection study in Africa: Lessons from Blantyre, Malawi](#)

[version 1; peer review: awaiting peer review]

Edna Nsomba *, Anthony E. Chirwa *, et al. Malawi Accelerated Research in Vaccines, Experimental Laboratory Systems (MARVELS) consortium

Abstract

Background

Human infection studies (HIS) also known as Controlled Human Infection Models (CHIM) are a relatively new concept in African countries to clinicians, scientists, and communities alike. We have introduced HIS/CHIM studies to Malawi during the last four years by developing an experimental human pneumococcal carriage model. This CHIM was used to test the efficacy of a licensed 13-valent Pneumococcal Conjugate Vaccine (PCV13) against experimental nasal pneumococcal carriage. Traditional and digital recruitment strategies into this novel trial were explored.

Objectives

To describe various methods of recruitment in this first CHIM study in Malawi.

Methods

The clinical trial within the context of which these data were recorded was registered with the Pan African Clinical Trials Registry (REF: PACTR202008503507113) on 03 August 2020. The project was conducted at the Malawi Liverpool Wellcome Programme (MLW) in Blantyre, Malawi between April 2021, and September 2022. Source populations were college students and community members within Blantyre. Recruitment strategies included sharing study information in written or visual form, community sensitization meetings, snowball contacts (word of mouth from previous volunteers), branded clothing and participating in radio and television programs.

Results

299 volunteers attended screening clinic, of whom 278 were recruited. Sixty-six recruited volunteers (23.7%) were college students and 212 (76.3%) were from the community. Snowball word-of-mouth contacting was the most successful recruitment strategy, with 201 (72.3%) participants recruited using this method. 195 (70.1%) were men of whom 149 (76.4%) joined the study through snowballing.

Conclusion or recommendation

Using a variety of recruitment strategies led to successful recruitment in this novel controlled human infection study. Most participants were recruited through snowballing.

* * * *

Think Tanks

Brookings [to 27 Apr 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 27 Apr 2024]

<https://www.cgdev.org/>

All Research [Selected]

No new digest content identified.

Chatham House [to 27 Apr 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

Research paper

Enhancing the security of civilians in conflict

This paper discusses six kinds of humanitarian arrangements intended to provide some security to civilians caught in armed conflict, outlining relevant international law, identifying operational challenges, and making recommendations for good practice.

24 April 2024

Council on Foreign Relations [to 27 Apr 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 27 Apr 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 27 Apr 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

[Donor Government Funding for Global Family Planning Declines to Lowest Level Since 2016](#)

April 24, 2024 News Release

A new KFF analysis finds donor government funding for family planning efforts in low- and middle-income countries totaled US\$1.35 billion in 2022, a decline of 9% (US\$129 million) compared to 2021 (\$1.48 billion). This figure marks the lowest level of funding since 2016 (\$1.31 billion). While some of the decline...

McKinsey Global Institute [to 27 Apr 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 27 Apr 2024]

<https://odi.org/en/publications/>

Publications [Selected]

[Beyond survival in displacement: rights essential for wellbeing](#)

22 April 2024

Briefing/policy paper

Wellbeing is not just a luxury to be enjoyed in times of peace or prosperity, but also a fundamental right during crisis. But, within a humanitarian system that prioritises the provision of what is deemed lifesaving assistance and the meeting of basic needs, interventions too often overlook large parts of what affected people really want, in order to live meaningful lives.

Pew Research Center [to 27 Apr 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 27 Apr 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

No new digest content identified.

Urban Institute [to 27 Apr 2024]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

World Economic Forum [to 27 Apr 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

[World Economic Forum Convenes Special Meeting on Global Collaboration, Growth and Energy for Development](#)

News 27 Apr 2024

- 1,000 government, business and civil society leaders to gather in Riyadh, Saudi Arabia
- Amid an increasingly complex global backdrop, the meeting aims to bridge the growing North-South divide and find collaborative solutions to shared challenges
- The meeting will drive action-oriented dialogue on three key themes: Inclusive Growth, Energy for Development, and Global Collaboration
- Watch livestreamed sessions from the meeting [here](#) and join the conversation on social media using #SpecialMeeting24

Riyadh, Saudi Arabia, 27 April 2024 – With geopolitical upheavals and complex economic challenges destabilizing a fractured world, the World Economic Forum Special Meeting on Global Collaboration, Growth and Energy for Development will convene 1,000 global leaders from 92 countries on 28-29 April, to support global dialogue and find actionable, collaborative and sustainable solutions to shared global challenges.

Building on the inaugural Growth Summit, held in Switzerland last year, the meeting will promote forward-thinking approaches to interconnected crises, while remaining realistic about shorter-term trade-offs. It will work to bridge the growing North-South divide on issues such as emerging economic policies, the energy transition and geopolitical shocks....

.....

.....

Public Consultations/Call for Inputs/Call for Papers

[Invitation for Public Comment: WHO principles for human genome access, use and sharing](#)

8 April 2024 **Consultation Period: 8th April 2024 – 3 May 2024**

Background:

For the potential of genomics to be realized, access to, use, and the sharing of human genome data is critical. Following the WHO's Science Council 2022 Report on Accelerating access to genomics for global health: promotion, implementation, collaboration, and ethical, legal, and social issues, WHO is implementing a programme of activities to promote equitable and fair access to genomics technologies for the benefit of people worldwide. As part of this, WHO is developing guiding principles for human genome data access, use and sharing. To develop these principles, a virtual consultation was held in January 2024 with an interdisciplinary group of participants. This consultation discussed the diverse perspectives on issues related to human genome data access, use and sharing; how a global set of principles from WHO may enable data access, use and sharing; and proposed initial principles. This was followed by an in-person meeting in March 2024 that

considered in detail the proposed principles. Following this meeting, a draft document was developed and comments on this document and the principles are now invited.

Feedback on the WHO Principles for human genome data access, use, and sharing Public feedback on this document is being solicited through this public consultation using the [comment form](#).

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * * *